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Abstract We describe a robust expression of human stromal
cell-derived factor-1K (SDF-1K) and SDF-1L, the members of
CXC-chemokine family, with a novel vector system based upon
Sendai virus, a non-segmented negative strand RNA virus.
Recombinant SDF-1K and SDF-1L were detected as a major
protein species in culture supernatants, reached as high as 10 Wg/
ml. This remarkable enrichment of the products allowed us to use
even the crude supernatants as the source for biological and
antiviral assays without further concentration nor purification
and will thus greatly facilitate to screen their genetically
engineered derivatives.
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1. Introduction
Stromal cell-derived factor (SDF-1), also named pre-B cell
growth-stimulating factor (PBSF), is a member of the CXC-
chemokine family. SDF-1 was initially de¢ned as a bone mar-
row stromal cell-derived soluble factor [1], but is subsequently
found to be considerably multi-functional as it is involved in
B lymphopoiesis, bone marrow hematopoiesis and cardiac
ventricular septal formation [2,3]. Human and murine SDF-
1 is known to arise in two forms, SDF-1K and SDF-1L, by
di¡erential splicing from a single gene. They di¡er in four
carboxy-terminal amino acid residues which are present in
SDF-1L and absent in SDF-1K [1,4]. Chemokines constitute
a large family of small chemotactic cytokines of 60^80 amino
acid residues. The members of this family have four conserved
cysteine residues which form two intra-molecular disul¢de
bridges [5]. There are two subfamilies of chemokines, CC-
chemokines and CXC-chemokines, which di¡er in the spacing
of the ¢rst two cysteine residues. The CC-chemokine subfam-
ily includes macrophage in£ammatory peptide-1K and -1L
(MIP-1K and MIP-1L), regulated on activation normal T
cell expressed and secreted (RANTES) and monocyte chemo-
attractant protein-1 (MCP-1). The CXC-chemokine subfamily
includes interleukin-8 (IL-8), platelet factor-4 (PF-4), in addi-
tion to SDF-1. Of these chemokines, SDF-1 appears to be
most e⁄cacious as a chemoattractant on resting T lympho-
cytes and monocytes [6].
Recently, both CC- and CXC-chemokines are attracting the
keenest attention, because their receptors were proved to be
used by human immunode¢ciency virus type 1 (HIV-1) as a
co-receptor for its entry into the CD4+ cells [7^13], and be-
cause they competitively block this virus-cell interaction [14^
18]. Co-receptor usage and hence inhibition of infection by
chemokines is strain speci¢c. For instance, macrophage
tropic/non-syncytium inducing strains need CCR-5 for their
entry into target cells [7,9^12] and their infection can be
blocked by the corresponding ligands, MIP-1K, MIP-1L, and
RANTES [14,16,18]. On the other hand, CXCR-4 serves as a
co-receptor for T cell line tropic/syncytium inducing strains
[8,13], and its ligand SDF-1 can block the infection [15,17].
These discoveries have not only greatly facilitated our under-
standing of HIV replication and pathogenesis but also opened
a novel possibility to treat HIV infection with chemokines or
chemokine derivatives.
MIP-1K, MIP-1L and RANTES, produced in E. coli, have
become commercially available and now widely used to get
more information on the mechanism of co-receptor mediated
HIV entry and its block by chemokines [7,18^21]. However,
E. coli-based production generally requires extensive, multi-
step puri¢cation of the product before use, and therefore is
not always feasible for testing many di¡erent, genetically en-
gineered derivatives. Extensive aggregation is often inevitable
particularly for such basic polypeptides as chemokines. Thus,
chemical synthesis of the original and modi¢ed versions has
been adopted. This approach is not only laborious, including
careful refolding, but also expensive. Puri¢cation of recombi-
nant chemokines produced in mammalian and other higher
vertebrate cells by recombinant viruses has not been reported.
We recently established a system to recover infectious Sen-
dai virus (SeV), a non-segmented negative strand RNA virus
in the family Paramyxoviridae, entirely from cDNA [22], and
further succeeded in applying the technology to insert a for-
eign gene of interest to SeV genome and express the gene in
extremely large quantities from an infectious recombinant SeV
[23,24]. Here, we made attempts to create recombinant SeV
expressing SDF-1K and SDF-1L to know whether or not this
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system can be applied for large quantity production of bio-
logically active cytokines which can be used with minimal
puri¢cation procedures. The SDF-1K and SDF-1L expressed
from recombinant viruses consistently reached in amounts as
high as 10 mg or more per liter of tissue culture medium. This
high level of accumulation of the products has allowed not
only the use of crude tissue culture medium as probes for
chemotaxis and antiviral assays but also their puri¢cation
by a single-step column chromatography. Thus, our system
represents a novel and useful option for providing SDF-1K
and SDF-1L and probably other chemokines and cytokines.
2. Materials and methods
2.1. Viruses and cells
HIV-1 strains NL43 [25], SF33 [26], and TK11 [27] and SIV mac
strain 239 [28] were grown in MT4 T cell line. HIV-1 strain SF162
[29], primary isolates #12, #15 and #37 [30,31] were propagated in
phytohemagglutinin-stimulated peripheral blood mononuclear cells
(PBMC). CV1 cells were grown in minimum essential medium
(MEM) supplemented with 10% fetal bovine serum (FBS). MT4 cells
were grown in RPMI-1640 supplemented with 10% FBS. Primary
chicken embryo ¢broblasts (CEF) were prepared as described previ-
ously [32], and maintained in MEM supplemented with 10% FBS.
After virus infection, CEF were maintained in MEM without serum.
PBMC from healthy seronegative donors were prepared and grown as
described previously [30].
2.2. Generation of recombinant Sendai viruses
Human SDF-1K or SDF-1L cDNAs were inserted just upstream of
the open reading frame of the 3P proximal N gene of SeV according to
the method described previously [22^24] to generate recombinant SeV,
SeV/SDF-1K or SeV/SDF-1L.
2.3. Northern blot
Total RNA was extracted using RNAzol-B (Tel-Test Inc., Texas)
from approximately 106 CEF infected with the SeVSDF-1K(+) at
various time points post infection (p.i.). The RNAs were ethanol
precipitated, dissolved in formamide/formaldehyde solution, then elec-
trophoresed in 1% agarose-formamide/MOPS gels, and capillary
transferred onto Hibond-N ¢lters (Amersham, UK). They were hy-
bridized with the SDF-1 speci¢c NotI fragment from pSeVSDF-1K(+)
probes that had been labeled with K-P32-dCTP using Multiprime
DNA Labeling System (Amersham).
2.4. Western blot
Culture supernatants of infected cells were electrophoresed in 15%
SDS-polyacrylamide gels [34]. The proteins in the gels were electro-
transferred onto PVDF membranes (Millipore, Bedford) and probed
with anti-SDF-1 antiserum, which was prepared by immunized rabbits
with multiple antigen peptide containing residues 33^45 (RFFESH-
VARANVK) synthesized by Research Benetics Inc. (Huntsville, AL)
[33].
2.5. Puri¢cation of SDF-1K and SDF-1L
Culture supernatants of CEF infected with SeV/SDF-1K or SeV/
SDF-1L were harvested 72 h after infection and the SeV viruses
were removed by centrifugation at 48 000Ug for 1 h at 4‡C. The
supernatant was applied to an 1 ml Hi-Trap heparin column (Phar-
macia, Uppsala, Sweden) equilibrated with 10 mM sodium phosphate
bu¡er, pH 7.2, on an FPLC system (Pharmacia, Uppsala, Sweden).
After washing with 5 ml of the same bu¡er, bound proteins were
eluted with 10 ml of linear gradient of 0.4^1.0 M NaCl in the same
bu¡er. Fractions were diluted more than 80-fold before assaying the
chemotactic or anti-HIV activity. Active fractions were collected.
2.6. Chemotaxis assay
Lymphocyte chemotaxis assays were performed according to the
method described by Bluel et al. [6]. Brie£y, human peripheral blood
lymphocytes were obtained from healthy donors by Ficoll-Histpaque
method. Monocytes were removed by 1-h steps of plastic adherence.
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Fig. 1. Construction of the plasmids pSeV/SDF-1K(+) and pSeV/
SDF-1L(+) which generate recombinant SeV/SDF-1K and SeV/SDF-
1L antigenomic RNAs, respectively. The ORFs of human SDF-1K
or SDF-1L followed by SeV transcriptional regulation signals E
(hatched box) and S (¢lled box) were ampli¢ed with NotI-tagged
primers and inserted to the NotI site in the parental pSeV18b(+)
which generate a full length copy of the antigenomic positive sense
of SeV RNA as described in Section 2.
Fig. 2. Expression of human SDF-1K and SDF-1L genes from SeV/
SDF-1K and SeV/SDF-1L. A: Northern blot hybridization. The
RNA extracted at various hours after infection designated on the
top of each lane from CEF infected with SeV/SDF-1K or wild-type
SeV was analyzed by Northern blot hybridization with probe specif-
ic for SDF-1 gene. B: SDS-PAGE. Proteins in 100 Wl of culture
supernatant of CEF infected with wild-type SeV (lane 1), SeV/SDF-
1K (lane 2), or SeV/SDF-1L (lane 3) were precipitated with ethanol
together with 10 Wg of BSA as carriers, and subjected to 15% SDS-
PAGE. The gel was stained with Coomassie brilliant blue. Lane 4
shows 10 Wg of BSA. C: Western blot analysis. Proteins resolved by
SDS-PAGE were electrotransferred onto PVDF membrane and
probed with anti-SDF-1 antiserum.
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Cells (5U105) in 100 Wl RPMI-1640 medium containing 0.25% human
serum albumin (HSA) were added to the upper chamber of a 5-Wm
pore polycarbonate Transwell culture insert (Coaster, Cambridge,
MA) and incubated with the indicated concentrations of proteins
for 3 h. Transmigrated cells were counted with a FACScan (Becton
Dickinson, San Jose, CA) for 20 s at 60 Wl/min.
2.7. Anti-HIV-1 assay
PHA-stimulated PBMC or MT4 cells (5U105) were incubated with
indicated concentrations of chemokines for 16 h, and then exposed to
1000 50% tissue culture infective dose of HIV-1 for 2 h at 37‡C. The
cells were washed twice with RPMI medium and maintained in the
culture medium for each cell type. Culture supernatants of the in-
fected cells were assayed for the levels of p24 core antigen (Abbott,
Wiesbaden-Delkenheim, Germany). Data points are the means of du-
plicate cultures.
2.8. Cell fusion assay
A recombinant vaccinia virus-based gene activation assay using a L-
galactosidase gene as a reporter was performed as described by Nuss-
baum et al. [35]. Brie£y, L cells were transfected with plasmid
pG1NT7L-gal with DOTAP and then infected with recombinant vac-
cinia virus expressing gp160 of HIV-1 strain NL43. MT4 cells were
infected with vTF7-3 [36], and then treated with 2-fold diluted culture
supernatant of CEF infected with SeV/SDF-1K or wild-type SeV.
After 16-h incubation at 31‡C, equal numbers (1U105) of L and
MT4 cells were mixed and incubated at 37‡C for 3 h. L-galactosidase
activity within cell lysate was measured by using chlorophenol red-L-
D-galactopyranoside as a substrate.
2.9. Luciferase assay
MT4 cells were incubated with or without 0.5 Wg/ml of SDF-1K for
16 h, and then transfected with 5 Wg of the plasmid carrying the
luciferase reporter gene under the control of HIV-1 LTR, pHIV-
1LTR/L-A-5P438, and 5 Wg of the tat expression plasmid, pcDL-
SRK/tat501, with DOTAP (Boehringer-Mannheim, Germany). Cells
were maintained in the presence or absence of 0.5 Wg/ml of SDF-1K
for additional 40 h and then lysed for luciferase assay [22].
2.10. Ca2 + in£ux assay
Freshly prepared PBMC were stimulated with PHA for 3 days in
RPMI without IL-2. Ca2 in£ux into PHA-stimulated PBMC upon
SDF-1K treatment was assayed as described previously [17].
3. Results
3.1. Generation of a recombinant SeV carrying human SDF-1K
gene
The SeV genome of 15-kb long negative sense RNA is or-
ganized starting with a short 3P-leader region, followed by six
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Fig. 3. Biological activities of SDF-1K. A: Chemotactic activity of SDF-1K. Culture supernatants of CEF infected with SeV/SDF-1K (a) or
wild-type SeV (b) were serially diluted and examined for their chemotactic activity. Error bars indicate standard deviations of duplicated data.
B: Inhibitory e¡ect of SDF-1K on cell fusion mediated by gp160 of HIV-1 strain NL43. Filled and hatched bars indicate L-galactosidase activ-
ity within cells treated with the culture supernatants of CEF infected with wild-type SeV and SeV/SDF-1K, respectively. Error bars indicate
standard deviations of duplicated data. C: E¡ect of SDF-1K on HIV-1 LTR-driven luciferase activity. MT4 cells were treated with culture
supernatants of CEF infected with wild-type SeV (WT) of SeV/SDF-1K (SDF-1K) followed by transfection with both pHIV-1LTR/L-A-5P438
and pcDL-SRK/tat501 (¢lled bars), or pHIV-1LTR/L-A-5P438 alone (hatched bars). Luciferase activity within cells was assayed 40 h after trans-
fection.
Fig. 4. A: E¡ect of PTX on chemotactic activity of SDF-1K.
Freshly prepared PBL were incubated at 37‡C for 16 h in the pres-
ence or absence of 100 ng/ml of PTX. Migration of PBL to 20-fold
diluted culture supernatants of CEF infected with SeV/SDF-1K was
performed as described in Section 2. Error bars indicate standard
deviations of duplicated data. B: E¡ect of PTX on SDF-1K medi-
ated Ca2 in£ux into PBMC. Dialyzed culture supernatants of CEF
infected with SeV/SDF-1K (SDF-1K) or wild-type SeV (wt) were
added at the time point indicated by arrows. C: E¡ect of PTX on
HIV-1 growth and SDF-1K mediated anti-HIV-1 activity. MT4 cells
were incubated at 37‡C for 16 h in the presence (+) or absence (3)
of 100 ng/ml of PTX, and treated with culture supernatants of CEF
infected with SeV/SDF-1K or wild-type SeV, and then infected with
NL43 strain of HIV-1. The levels of p24 core antigen in the culture
supernatants were assayed 3 days after infection. Data points are
mean actual £uctuations of duplicated culture.
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structural genes and ending with the short 5P-trailer region
[37^39]. There is only a single promoter for RNA polymerase
consisting of L and P proteins [40], at the 3P end. By recog-
nizing the stop or end (E) (termination/polyadenylation) and
restart (S) signals, the polymerase gives rise to leader RNA
and each mRNA species. The plasmid pSeV18(+) carries a
cDNA copy of SeV full length antigenome (positive strand
RNA), in which an additional 18 synthetic nucleotides con-
taining unique NotI site was inserted. This insertion was done
within the ¢rst gene locus (N gene) and just upstream of its
ORF, and serves as the site for further insertion of a foreign
gene of interest [23]. Placing the foreign gene in this 3P-termi-
nal ¢rst locus expects the highest expression, because of polar
attenuation of gene expression toward the 5P-terminus [41].
The entire viral sequence containing the 18-nucleotide inser-
tion was placed between the T7 promoter and the hepatitis
delta virus ribozyme. The latter was used to generate a precise
3P end.
A 348-bp DNA fragment containing entire coding frame of
human SDF-1K gene (267 bp) followed by a new set of syn-
thetic E and S signals with intervening three nucleotides was
ampli¢ed with NotI-tagged primers and inserted into the NotI
site in pSev18b(+), generating pSeVSDF-1K(+) (Fig. 1). In
the cells infected with recovered recombinant virus, the S sig-
nal originally used for the N gene start directs the initiation of
inserted SDF-1K gene transcription, and the introduced syn-
thetic E and S signals direct the termination of inserted SDF-
1K gene and the transcription initiation of the downstream N
gene, respectively. pSeVSDF-1K(+) was transfected to v-TF7-
3 infected LLCMK2 cells and the T7-driven full length re-
combinant SeV RNA genomes were encapsulated with N, P
and L proteins, which were derived from the cotransfected
respective plasmids. Following a 40-h incubation to allow
initiation of the infectious cycle and generation of progeny,
the transfected cells were injected into embryonated chicken
eggs to amplify the recovered virus. After a successive passage
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Table 1
E¡ect of SDF-1K on the growth of several HIV-1 and SIV mac strains
Strain Phenotype p24 (ng/ml)
Control SDF-1K (0.5 Wg/ml)
NL43a SI/T cell line tropic 54.44 1.40
SF33a SI/T cell line tropic 78.50 6.40
TK11a SI/T cell line tropic 355.00 26.00
#15b SI 100.23 1.36
SF162b NSI/macrophage tropic 10.43 12.35
#12b NSI 27.91 17.70
#37b NSI 22.01 20.00
SIV mac239a T cell line tropic 4.81c 6.22c
SI and NSI indicate syncytium inducing and non-syncytium inducing phenotype, respectively. Data points are means of duplicate cultures.
aInhibition by SDF-1K in MT4 cells was evaluated at day 3 after infection.
bInhibition by SDF-1K in PBMC cultures was evaluated at day 7 after infection.
cSIV mac p27 core antigen levels are shown.
Fig. 5. Left panel: Puri¢cation of SDF-1K. SDF-1K was puri¢ed from the culture supernatant of CEF infected with SeV/SDF-1K by binding to
Hi-Trap heparin column. Bars in the column chromatogram indicate chemotactic activity. Right panel: SDS-PAGE of puri¢ed SDF-1K and
SDF-1L. Three active fractions shown by asterisks in the left panel were pooled and subjected to 15% SDS-PAGE. Proteins were silver-stained
(lanes 1 and 2) or probed with anti-SDF-1 serum after electrotransferring to PVDF membrane (lanes 3 and 4). Positions of molecular weight
markers are shown. Lanes 1 and 3, SDF-1K ; lanes 2 and 4, SDF-1L.
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in eggs, the recombinant virus reached a titer of over 109
PFU/ml comparable to that of the wild-type SeV. This second
passage, initiated at a dilution of 1036, resulted in complete
elimination of helper vTF7-3 present in an amount of 104 to
105 PFU/ml. Nucleotide sequencing of the recombinant virus
revealed that there was no accidental nucleotide substitution
within the inserted SDF-1K gene. The recovered virus was
named SeV/SDF-1K.
3.2. Anti-HIV-1 and chemotactic activities of SDF-1K
expressed from SeV/SDF-1
SeV has a broad host range and reaches quite a high copy
number in susceptible cells. In previous experiments, we found
that expression levels were the highest in CV1, a monkey
kidney cell line [23,24]. Here, we found that primary chicken
embryo ¢broblasts (CEF) were still more productive, and used
in all subsequent studies. In CEF infected with SeV/SDF-1K,
the transcripts speci¢c to SDF-1K with an expected size of
approximately 400 bases were detected (Fig. 2A), and a poly-
peptide with a molecular mass of 8 kDa was observed as a
major protein constituent in the culture supernatant (Fig. 2B).
This protein species was absent in wild-type SeV infected £u-
id, and reacted speci¢cally with rabbit serum immunized with
13-mer peptides derived from human SDF-1K sequence in
Western blotting (Fig. 2C). These results demonstrated that
substantial amounts of SDF-1K were produced from the re-
combinant SeV and secreted into the culture supernatant.
After a 72-h incubation, the amount of SDF-1K in the culture
£uid reached over 10 Wg/ml.
Because the culture £uid e⁄ciently attracted freshly pre-
pared human peripheral blood lymphocytes (PBL) in chemo-
taxis assays (Fig. 3A), the recombinant SDF-1K was function-
ally authentic. The recombinant SDF-1K suppressed the
replication of three di¡erent T cell line tropic HIV-1 strains,
NL43, SF33 and TK11, in the MT4 T cell line, and one
syncytium inducing primary isolate #15 in PBMC culture
(Table 1). The SDF-1K did not suppress the replication of
macrophage tropic strain SF162, nor two non-syncytium in-
ducing primary isolates, #12 and #37, in PBMC cultures (Ta-
ble 1). The recombinant SDF-1K did not show any inhibitory
activity for simian immunode¢ciency virus (SIV) strain
mac239 in MT4 cells (Table 1). These results are consistent
with the expected speci¢city of antiviral activities of SDF-1K
and thus con¢rmed the biological authenticity of the SeV-
derived recombinant SDF-1K. We further demonstrated that
the recombinant SDF-1K indeed inhibited the step of mem-
brane fusion, but not the viral transcription (Fig. 3B and C).
3.3. E¡ect of a G protein blocker on SDF-1 mediated inhibition
of HIV-1 growth
Pretreatment of PBL with 100 ng/ml of pertussis toxin
(PTX) for 18 h completely abolished the chemotactic activity
of SDF-1K (Fig. 4A). Ca2 mobilization into PBL mediated
by SDF-1K was also inhibited by this reagent (Fig. 4B), con-
¢rming that SDF-1K transduces signals mediated by GKi-
coupled receptor. However, the same concentration of PTX
did not a¡ect the inhibitory activity of SDF-1K in HIV-1
growth (Fig. 4C). The blocker alone did not a¡ect HIV-1
replication at all. These results indicated that the G protein
mediated signal transduction is neither a prerequisite for HIV-
1 entry nor essential for the inhibitory action of SDF-1K.
3.4. Puri¢cation of the recombinant SDF-1K from culture
supernatants
An a⁄nity heparin column chromatography was performed
to purify SDF-1K from the culture supernatant of SeV/SDF-
1K infected CEF. The chemotactic and anti-HIV-1 activity
were co-eluted with a single 8 kDa polypeptide in the chro-
matography (Fig. 5). We consistently obtained at least 50 Wg
of puri¢ed SDF-1K from 50 ml crude culture supernatant.
Amino acid sequencing demonstrated the NH2-terminal
KPVSLSYRXPXR, identical to the reported sequence of
SDF-1K. In this NH2-terminal peptide, X should be read as
C, because it cannot be resolved by the sequencing method
employed. In the puri¢ed SDF-1K preparation, we detected a
small amount of protein with the N-terminal sequence,
SYRXPXRFFE, which lacked the ¢rst ¢ve amino acid resi-
dues of the SDF-1K sequence. This minor species of the NH2-
terminal sequence was also reported to be present in the SDF-
1K preparation puri¢ed from a bone marrow stromal cell line
[6] and has been shown to be functionally inactive in both
chemotactic and HIV-1 inhibition [15].
3.5. Comparison of SDF-1K and SDF-1L
The human and murine SDF-1 gene gives rise to two forms,
SDF-1K and SDF-1L, by alternative splicing. They di¡er in
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Fig. 6. A: Chemotactic activity of SDF-1K and SDF-1L. Puri¢ed
SDF-1K (E) and SDF-1L (F) were serially diluted and assayed for
the chemotactic activity. B: Anti-HIV-1 activity of SDF-1K and
SDF-1L. MT4 cells were treated with 200 ng/ml of puri¢ed SDF-1K
(E) or SDF-1L (F), and then infected with NL43 strain of HIV-1.
The levels of p24 core antigen in the culture supernatants were as-
sayed periodically. Data points are mean actual £uctuations of du-
plicate cultures. Filled triangles show cultures which were not
treated with chemokines.
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the carboxy-terminal four amino acid residues, which are
present in SDF-1L and absent in SDF-1K [1,4]. We also suc-
cessfully constructed a recombinant SeV expressing SDF-1L
(SeV/SDF-1L) (Fig. 1). As in the case of SDF-1K, the amount
of SDF-1L reached over 10 Wg/ml in the culture supernatant
of CEF infected with SeV/SDF-1L, and readily puri¢ed by
heparin column chromatography (Fig. 5). Consistent with
the fact that SDF-1L has additional four amino acid residues,
it migrated slightly more slowly than SDF-1K in SDS-PAGE
(Figs. 2B and 5).
The chemotactic and anti-HIV-1 activities of SDF-1L were
examined and compared with those of SDF-1K. SDF-1L was
found to attract freshly prepared PBL in chemotaxis assay
and suppressed HIV-1 strain NL43 as e⁄ciently as did
SDF-1K (Fig. 6).
4. Discussion
In this paper, we have described SeV-based expression of
both SDF-1K and SDF-1L. They were of equal e⁄cacy in
chemotactic activity on freshly prepared PBL and inhibiting
HIV-1 replication. Their speci¢city was demonstrated by se-
lective inhibition of T cell line tropic laboratory strains and SI
type primary isolates. In most previous papers on SDF-1K, it
was either chemically synthesized or physiologically produced
from bone marrow stromal cells [6,15,17,19,42^45]. In the
latter, native molecules can be obtained in conditioned media
but in an estimated amount of only 1 Wg/ml at most. In the
former, the primary product should be oxidized to form di-
sul¢de bridges, and then carefully puri¢ed by high perform-
ance liquid chromatography. Moreover, the production is la-
borious and expensive. Only a single round of synthesis of
1 mg may require numerous days and cost. In our expression
system, SDF-1K as well as SDF-1L accumulated extensively,
reaching as high as 10 Wg/ml or more, in the culture super-
natants. Thus, the product existed as a major protein constit-
uent in the supernatant, indicating its remarkable enrichment
already in the crude material. Because of this high level of
production and because an amount around 200 ng/ml is su⁄-
cient for chemotaxis and antiviral assay, culture supernatants
without further condensation and puri¢cation could be con-
veniently used as the source of SDF-1K and SDF-1L for var-
ious experiments described above. It will be thus also easy to
test the functions of derivatives produced from recombinant
viruses following various engineering of their genes.
SDF-1K we generated e⁄ciently suppressed replication of T
cell line tropic or primary SI strains but not macrophage
tropic or NSI strains of HIV-1. It was recently reported
that simian immunode¢ciency virus (SIV) strains do not uti-
lize CXCR-4 as a co-receptor, although they can grow very
well in T cell lines which lack another co-receptor, CCR-5
[46^48]. Co-receptors for SIV were recently identi¢ed and
named BOB/gpr1, Bonzo and gpr15 [49,50]. Consistent with
these ¢ndings, recombinant SDF-1K did not suppress replica-
tion of SIV strain mac239 at all even in the MT4 T cell line.
The transcripts of murine SDF-1K and SDF-1L were ob-
served in many tissues including the brain, heart, lung, kidney,
thymus, liver, and spleen, and the amount of transcripts of
SDF-1K was always higher than that of SDF-1L [1]. In the
present study, we found that SDF-1K and SDF-1L were
equally e¡ective in both chemotaxis and virus inhibition. On
the other hand, it is reported that negative charges in the C-
terminus of CC-chemokine MIP-1K were important for its
tendency to form self-aggregation [51]. Since two out of
four amino acid residues speci¢c for SDF-1L are basic lysine
residues, SDF-1K and SDF-1L may di¡er in their tendency to
form self-aggregates. Thus, SDF-1K and SDF-1L may display
di¡erent rates of in vivo spread, and therefore their contribu-
tion to in vivo physiology and the e¡ects on HIV-1 contain-
ment may di¡er both quantitatively and qualitatively. It will
be important to learn the physical properties and antiviral
actions of recombinant SDF-1K and SDF-1L in vivo.
Acknowledgements: vTF7-3 and pG1T7L-gal are kindly supplied by
B. Moss and E. Berger, respectively. This work was supported by the
grants from the Ministry of Education, Science, Sports and Culture,
the Ministry of Health and Welfare, the Science and Technology
Agency of Japanese Government, and those from the Human Science
Promotion Foundation and the Organization for Drug ADR Relief,
R and D Promotion and Product Review of Japan.
References
[1] Tashiro, K., Tada, H., Heilker, R., Shirozu, M., Nakano, T. and
Honjo, T. (1993) Science 261, 600^603.
[2] Nagasawa, T., Kikutani, H. and Kishimoto, T. (1994) Proc. Natl.
Acad. Sci. USA 91, 2305^2309.
[3] Nagasawa, T., Hirota, S., Tachibana, K., Takakura, N., Nishi-
kawa, S., Kitamura, Y., Yoshida, H., Kikutani, H. and Kishi-
moto, T. (1996) Nature 382, 635^638.
[4] Shirozu, M., Nakano, T., Inazawa, J., Tashiro, K., Tada, H.,
Shinohara, T. and Honjo, T. (1995) Genomics 28, 495^500.
[5] Rollins, B.J. (1997) Blood 90, 909^928.
[6] Bluel, C.C., Fuhlbrigge, R.C., Casanovas, J.M., Aiuti, A. and
Springer, T.A. (1996) J. Exp. Med. 184, 1101^1109.
[7] Alkhatib, G., Combadiere, C., Broder, C.C., Feng, Y., Kennedy,
P.E., Murphy, P.M. and Berger, E.A. (1996) Science 272, 1955^
1958.
[8] Berson, J.F., Long, D., Doranz, B.J., Rucker, J., Jirik, F.R. and
Doms, R.W. (1996) J. Virol. 70, 6288^6295.
[9] Choe, H., Farzan, M., Sun, Y., Sullivan, N., Rollins, B., Ponath,
P.D., Wu, L., Mackay, C.R., LaRosa, G. and Newman, W. et al.
(1996) Cell 85, 1135^1148.
[10] Deng, H., Liu, R., Ellmerier, W., Choe, S., Unutmaz, D., Burk-
hart, M., Di Marzio, P., Marmon, S., Sutton, R.E. and Hill,
C.M. et al. (1996) Nature 381, 661^666.
[11] Doranz, B.J., Rucker, J., Yi, Y., Smyth, R.J., Samson, M.,
Peiper, S.C., Parmentier, M., Collman, R.G. and Doms, R.W.
(1996) Cell 85, 1149^1158.
[12] Dragic, T., Litwin, V., Allaway, G.P., Martin, S.R., Huang, Y.,
Nagashima, K.A., Cayanan, C., Maddon, P.J., Koup, R.A.,
Moore, J.P. and Paxton, W.A. (1996) Nature 381, 667^673.
[13] Feng, Y., Broder, C.C., Kennedy, P.E. and Berger, E.A. (1996)
Science 272, 872^877.
[14] Arenzana-Seisdedos, F., Virelizier, J.L., Rousset, D., Clark-
Lewis, I., Loetscher, P., Moser, B. and Baggiolini, M. (1996)
Nature 383, 400.
[15] Bleul, C.C., Farzan, M., Choe, H., Parolin, C., Clark-Lewis, I.,
Sodroski, J. and Springer, T.A. (1996) Nature 382, 829^833.
[16] Cocchi, F., DeVico, A.L., Garzino-demo, A., Arya, S.K., Gallo,
R.C. and Lusso, P. (1995) Science 270, 1811^1815.
[17] Oberlin, E., Amara, A., Bachelerie, F., Bessia, C., Virelizier, J.L.,
Arenzana-Seisdedos, F., Schwartz, O., Heard, J.M., Clark-lewis,
I. and Legler, D.F. et al. (1996) Nature 382, 833^835.
[18] Oravecz, T., Pall, M. and Norcross, M.A. (1996) J. Immunol.
157, 1329^1332.
[19] Aiutu, A., Webb, I.J., Bluel, C., Springer, T. and Gutierrez-Ra-
mos, J.C. (1997) J. Exp. Med. 185, 111^120.
[20] Trkola, A., Dragic, T., Arthos, J., Binley, J., Olson, W.C., All-
away, G.P., Cheng-Mayer, C., Robinson, J., Maddon, P.J. and
Moore, J.P. (1996) Nature 384, 184^187.
[21] Wu, L., Gerard, N.P., Wyatt, R., Choe, H., Parolin, C., Ru⁄ng,
N., Borsetti, A., Cardoso, A.A., Desjardin, E. and Newman, W.
et al. (1996) Nature 384, 179^183.
FEBS 19974 19-3-98
C. Moriya et al./FEBS Letters 425 (1998) 105^111110
[22] Kato, A., Sakai, Y., Shioda, T., Kondo, T., Nakanishi, M. and
Nagai, Y. (1996) Genes Cells 1, 569^579.
[23] Hasan, M.K., Kato, A., Shioda, T., Sakai, Y., Yu, D. and Nagai,
Y. (1997) J. Gen. Virol. 78, 2813^2820.
[24] Yu, D., Shioda, T., Kato, A., Hasan, M.K., Sakai, Y. and Nagai,
Y. (1997) Genes Cells 2, 457^466.
[25] Adachi, A., Gendelman, H.E., Koenig, S., Folks, T., Willey, R.,
Rabson, A. and Martin, M.A. (1986) J. Virol. 59, 284^291.
[26] York-Higgins, D., Cheng-Mayer, C., Bauer, D., Levy, J.A. and
Dina, D. (1990) J. Virol. 64, 4016^4020.
[27] Oka, S., Ida, S., Shioda, T., Takebe, Y., Kobayashi, N., Shibuya,
Y., Ohyama, K., Momota, K., Kimura, S. and Shimada, K.
(1994) AIDS Res. Hum. Retroviruses 10, 271^277.
[28] Naidu, Y.M., Kestler III, H.W., Li, Y., Butler, C.V., Silva, D.P.,
Schmidt, D.K., Troup, C.D., Sehgal, P.K., Sonigo, P., Daniel,
M. and Desrosiers, R.C. (1988) J. Virol. 62, 4691^4696.
[29] Shioda, T., Levy, J.A. and Cheng-Mayer, C. (1991) Nature
(Lond.) 234, 167^169.
[30] Shioda, T., Oka, S., Xin, X., Liu, H., Harukuni, R., Kurotani,
A., Fukushima, M., Hasan, M.K., Shiino, T., Takebe, Y., Iwa-
moto, A. and Nagai, Y. (1997) J. Virol. 71, 4871^4881.
[31] Xin, X., Shioda, T., Fukushima, M., Hu, H., Oka, S., Iwamoto,
A. and Nagai, Y. Arch. Virol., in press.
[32] Hanafusa, H. (1969) Proc. Natl. Acad. Sci. USA 63, 318^325.
[33] Tam, J.P. (1988) Proc. Natl. Acad. Sci. USA 85, 5409^5413.
[34] Laemmli, U.K. (1970) Nature (Lond.) 227, 680^685.
[35] Nussbaum, O., Broder, C.C. and Berger, E.A. (1994) J. Virol. 68,
5411^5422.
[36] Fuerst, T.R., Niles, E.G., Studier, F.W. and Moss, B. (1986)
Proc. Natl. Acad. Sci. USA 83, 8122^8126.
[37] Hidaka, Y., Kanda, T., Iwasaki, K., Nomoto, A., Shioda, T. and
Shibuta, H. (1984) Nucleic Acids Res. 12, 7965^7973.
[38] Shioda, T., Hidaka, Y., Kanda, T., Shibuta, H., Nomoto, A. and
Iwasaki, K. (1983) Nucleic Acids Res. 11, 7317^7330.
[39] Shioda, T., Iwasaki, K. and Shibuta, H. (1986) Nucleic Acids
Res. 14, 1545^1563.
[40] Hamaguchi, M., Yoshida, T., Nishikawa, K., Naruse, H. and
Nagai, Y. (1983) Virology 128, 105^117.
[41] Lamb, R.A. and Kolakofsky, D. (1996) in: B.N. Fields, D.M.
Knipe and P.M. Howley (Eds.), Fields Virology, 3rd Edn., Raven
Press, New York, pp. 1177^1204.
[42] Amara, A., Gall, S.L., Schwarts, O., Salamero, J., Montes, M.,
Loetscher, P., Baggiolini, M., Virelizier, J.-L. and Arenzana-Seis-
dedos, F. (1997) J. Exp. Med. 186, 139^146.
[43] Murakami, T., Nakajima, T., Koyanagi, Y., Tachibana, K., Fu-
jii, N., Tamamura, H., Yoshida, N., Waki, M., Matsumoto, A.,
Yoshie, O., Kishimoto, T., Yamamoto, N. and Nagasawa, T.
(1997) J. Exp. Med., in press.
[44] Nagasawa, T., Nakajima, T., Tachibana, K., Iizawa, H., Bluel,
C.C., Yoshie, O., Matsushima, K., Yoshida, N., Springer, T.A.
and Kishimoto, T. (1996) Proc. Natl. Acad. Sci. USA 93, 14726^
14729.
[45] Tachibana, K., Nakajima, T., Sato, A., Igarashi, K., Shida, H.,
Iizasa, H., Yoshida, N., Yoshie, O., Kishimoto, T. and Nagasa-
wa, T. (1997) J. Exp. Med. 185, 1865^1870.
[46] Chen, Z., Zhou, P., Ho, D.D., Landau, N. and Marx, P. (1997)
J. Virol. 71, 2705^2714.
[47] Edinger, A.L., Amedee, A., Miller, K., Doranz, B.J., Enders, M.,
Sharron, M., Samson, M., Liu, Z.-H., Clements, J.E., Murphey-
Corb, M., Peiper, S.C., Parmentier, M., Broder, C.C. and Doms,
R.W. (1997) Proc. Natl. Acad. Sci. USA 94, 4005^4010.
[48] Marcon, L., Choe, H., Martin, K.A., Farzan, M., Ponath, P.D.,
Wu, L., Newman, W., Gerard, N., Gerard, C. and Sodroski, J.
(1997) J. Virol. 71, 2522^2527.
[49] Deng, H., Unutmaz, D., Ramani, V.N.K. and Littman, D.R.
(1997) Nature 388, 296^300.
[50] Farzan, M., Choe, H., Martin, K., Marcon, L., Hofmann, W.,
Karlsson, G., Sun, Y., Barrett, P., Marchand, N., Sullivan, N.,
Gerard, N., Gerard, C. and Sodroski, J. (1997) J. Exp. Med. 186,
405^411.
[51] Graham, G.J., MacKenzie, J., Lowe, S., Tsang, M.L.-S., Weath-
erbee, J.A., Issacson, A., Medicherla, J., Fang, F., Wilkinson,
P.C. and Pragnell, I.B. (1994) J. Biol. Chem. 269, 4974^4978.
FEBS 19974 19-3-98
C. Moriya et al./FEBS Letters 425 (1998) 105^111 111
